{"id":"NCT00878072","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis","officialTitle":"A Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2009-03-25","primaryCompletion":"2010-06-02","completion":"2010-06-02","firstPosted":"2009-04-08","resultsPosted":"2021-06-25","lastUpdate":"2021-06-25"},"enrollment":53,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Herpes Labialis"],"interventions":[{"type":"DRUG","name":"Famciclovir","otherNames":[]}],"arms":[{"label":"Famciclovir","type":"EXPERIMENTAL"}],"summary":"This study will assess the safety, tolerability of a single 1500 mg dose of famciclovir in 50 adolescents with recurrent herpes labialis. Eight of the 50 adolescents will also participate in the pharmacokinetics (PK) assessment of famciclovir single 1500 mg dose","primaryOutcome":{"measure":"Number of Participants Reported Adverse Events (AEs), Serious Adverse Events (SAEs)","timeFrame":"From Start of the Study up to Day 36","effectByArm":[{"arm":"Famciclovir (Participants Aged 12 to Less Than [<] 15 Years)","deltaMin":6,"sd":null},{"arm":"Famciclovir (Participants Aged 15 to Less Than [<] 18 Years)","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":["21178655"],"seeAlso":["http://www.adolescentcoldsoresstudy.com","http://www.novartisclinicaltrials.com/webapp/portals/AdolescentColdSoresStudy/page.do"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":28},"commonTop":["Dizziness","Headache","Anaemia","Lymphadenopathy","Abdominal pain upper"]}}